Avanos Medical (NYSE:AVNS) Issues FY 2026 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.900-1.100 for the period, compared to the consensus EPS estimate of 1.030. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $704.7 million.

Analyst Ratings Changes

A number of analysts have recently issued reports on AVNS shares. Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Avanos Medical currently has a consensus rating of “Reduce”.

Avanos Medical Stock Performance

Avanos Medical stock traded up $0.08 during midday trading on Wednesday, hitting $13.72. The company’s stock had a trading volume of 11,192 shares, compared to its average volume of 569,608. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. The company has a market cap of $636.79 million, a price-to-earnings ratio of -1.35 and a beta of 1.09. Avanos Medical has a 1-year low of $9.30 and a 1-year high of $16.63. The company has a 50-day moving average price of $12.90 and a two-hundred day moving average price of $12.04.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The business had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.70 million. During the same period in the previous year, the company posted $0.43 earnings per share. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, sell-side analysts predict that Avanos Medical will post 1.32 earnings per share for the current year.

Key Stories Impacting Avanos Medical

Here are the key news stories impacting Avanos Medical this week:

• Positive Sentiment: Q4 results included a beat on reported revenue and on the consensus EPS metric: revenue of $180.9M and an EPS figure that topped Street estimates, and the company highlighted full-year revenue that met/exceeded targets and 6% organic growth in strategic segments. Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results
• Positive Sentiment: Management reiterated cost-transformation programs expected to deliver $15–$20M of incremental annualized savings by end of 2026, which should help margins over time. Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results
• Neutral Sentiment: The company released an earnings slide deck and hosted a conference call; the slide deck and transcript provide detail for investors evaluating the quality of the beat and the assumptions behind guidance. View Slide Deck
• Negative Sentiment: FY2026 EPS guidance of $0.90–$1.10 came in slightly below the consensus (~$1.03 midpoint), and revenue guidance of $700–720M only modestly exceeded consensus — investors focused on the EPS miss to the Street midpoint, which pressured the stock. MarketBeat: Q4 release and guidance
• Negative Sentiment: There was apparent confusion in call/transcript coverage (some transcripts reported an EPS miss or different EPS metrics), which likely amplified investor concern over one-time items, accounting distinctions (GAAP vs. adjusted), and clarity on profitability recovery. Mixed messages from the call increased selling pressure. InsiderMonkey: Q4 earnings call transcript
• Negative Sentiment: Year-over-year EPS declined (Q4 EPS down from prior-year levels) and the company still shows a negative net margin, which keeps investors focused on execution risk despite the operational positives. Seeking Alpha: Q4 results & presentation

Institutional Trading of Avanos Medical

A number of institutional investors and hedge funds have recently made changes to their positions in AVNS. Russell Investments Group Ltd. boosted its stake in shares of Avanos Medical by 969.3% during the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after purchasing an additional 2,307 shares in the last quarter. Wexford Capital LP acquired a new stake in Avanos Medical during the 3rd quarter worth approximately $70,000. Tower Research Capital LLC TRC grew its holdings in Avanos Medical by 433.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after acquiring an additional 5,083 shares during the last quarter. Quantessence Capital LLC acquired a new position in Avanos Medical in the 3rd quarter valued at approximately $116,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Avanos Medical during the fourth quarter valued at $122,000. Institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.